LON:SPI - Spire Healthcare Group Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 271.75
  • Forecasted Upside: 17.90 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
GBX 230.50
▼ -7.5 (-3.15%)

This chart shows the closing price for SPI by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Spire Healthcare Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SPI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SPI

Analyst Price Target is GBX 271.75
▲ +17.90% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Spire Healthcare Group in the last 3 months. The average price target is GBX 271.75, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a 17.90% upside from the last price of GBX 230.50.

This chart shows the closing price for SPI for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Spire Healthcare Group. This rating has held steady since July 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
1/11/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
4/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 5 hold ratings
  • 0 sell ratings
7/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/8/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/6/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/6/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/30/2022JPMorgan Chase & Co.Lower Price TargetOverweightGBX 347 ➝ GBX 237
6/30/2022Berenberg BankReiterated RatingBuyGBX 300
6/21/2022Berenberg BankReiterated RatingHoldGBX 300
5/31/2022BarclaysReiterated RatingOverweightGBX 310
4/5/2022BarclaysReiterated RatingOverweightGBX 310
3/24/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 240
3/11/2022BarclaysBoost Price TargetOverweightGBX 300 ➝ GBX 310
3/10/2022JPMorgan Chase & Co.Boost Price TargetOverweightGBX 296 ➝ GBX 347
2/4/2022Royal Bank of CanadaReiterated RatingSector PerformGBX 240
1/4/2022JPMorgan Chase & Co.Reiterated RatingOverweight
12/14/2021BarclaysReiterated RatingOverweightGBX 300
12/3/2021BarclaysReiterated RatingOverweightGBX 300
10/21/2021BarclaysReiterated RatingOverweightGBX 280
9/10/2021BarclaysUpgradeOverweightGBX 165 ➝ GBX 280
5/27/2021Liberum CapitalReiterated RatingHoldGBX 180
5/26/2021Peel HuntReiterated RatingBuyGBX 233
5/26/2021Peel HuntReiterated RatingBuyGBX 233
5/13/2021Numis SecuritiesReiterated RatingAddGBX 180
4/8/2021Royal Bank of CanadaBoost Price TargetOutperformGBX 169 ➝ GBX 200
2/9/2021Liberum CapitalDowngradeHoldGBX 180
9/28/2020JPMorgan Chase & Co.UpgradeOverweightGBX 136 ➝ GBX 175
7/27/2020UBS GroupLower Price TargetNeutralGBX 121 ➝ GBX 97
7/22/2020BarclaysReiterated RatingUnderweight
7/10/2020Morgan StanleyDowngradeEqual weightGBX 156 ➝ GBX 99
7/8/2020Jefferies Financial GroupReiterated RatingUnderperformGBX 113 ➝ GBX 67
7/2/2020Liberum CapitalReiterated RatingHold
7/1/2020Peel HuntReiterated RatingBuy
6/3/2020Peel HuntReiterated RatingBuy
5/14/2020Peel HuntReiterated RatingBuy
5/11/2020Royal Bank of CanadaDowngradeSector PerformerGBX 100
5/1/2020Peel HuntReiterated RatingBuy
4/24/2020Peel HuntReiterated RatingBuy
4/14/2020Peel HuntReiterated RatingBuy
4/7/2020Peel HuntReiterated RatingBuy
4/7/2020Liberum CapitalReiterated RatingHold
4/1/2020Peel HuntReiterated RatingBuy
4/1/2020Liberum CapitalReiterated RatingHold
3/24/2020Royal Bank of CanadaReiterated RatingOutperform
3/19/2020Peel HuntUpgradeBuy
3/18/2020Royal Bank of CanadaLower Price TargetOutperformGBX 149 ➝ GBX 100
3/18/2020Liberum CapitalReiterated RatingHold
3/13/2020Peel HuntReiterated RatingAdd
3/10/2020Liberum CapitalLower Price TargetHoldGBX 133 ➝ GBX 125
3/5/2020Peel HuntReiterated RatingAdd
2/11/2020UBS GroupBoost Price TargetNeutralGBX 117 ➝ GBX 121
2/5/2020Peel HuntReiterated RatingAdd
1/27/2020Liberum CapitalReiterated RatingHold
1/27/2020Peel HuntReiterated RatingAdd
1/21/2020Jefferies Financial GroupDowngradeUnderperformGBX 106 ➝ GBX 113
1/16/2020Peel HuntReiterated RatingAdd
1/13/2020Liberum CapitalBoost Price TargetHoldGBX 125 ➝ GBX 133
1/8/2020Peel HuntReiterated RatingAddGBX 155
1/7/2020BarclaysReiterated RatingUnderweight
1/7/2020Peel HuntReiterated RatingAddGBX 155
12/13/2019Peel HuntReiterated RatingAdd
12/5/2019Peel HuntReiterated RatingAdd
11/15/2019Jefferies Financial GroupReiterated RatingHold
11/12/2019Liberum CapitalBoost Price TargetHoldGBX 115 ➝ GBX 120
11/1/2019Peel HuntReiterated RatingAdd
9/16/2019Peel HuntReiterated RatingAddGBX 155
9/16/2019UBS GroupReiterated RatingNeutralGBX 120
9/16/2019Peel HuntUpgradeAddGBX 155
9/9/2019Royal Bank of CanadaReiterated RatingOutperformGBX 149
9/2/2019Peel HuntReiterated RatingHold
8/9/2019BarclaysReiterated RatingUnderweightGBX 115
8/5/2019Liberum CapitalReiterated RatingHold
8/1/2019Peel HuntReiterated RatingHold
7/11/2019Peel HuntReiterated RatingHold
7/11/2019Liberum CapitalReiterated RatingHold
7/3/2019Peel HuntReiterated RatingHold
7/2/2019UBS GroupInitiated CoverageNeutralGBX 120
6/4/2019Peel HuntReiterated RatingHold
5/16/2019Numis SecuritiesReiterated RatingBuyGBX 280 ➝ GBX 163
5/16/2019Peel HuntReiterated RatingHold
5/10/2019BarclaysReiterated RatingUnderweightGBX 115
5/2/2019Peel HuntReiterated RatingHold
4/12/2019BarclaysLower Price TargetUnderweightGBX 130 ➝ GBX 115
4/2/2019Peel HuntReiterated RatingHold
3/25/2019JPMorgan Chase & Co.Lower Price TargetNeutralGBX 146 ➝ GBX 127
3/14/2019Liberum CapitalReiterated RatingHold
3/13/2019Credit Suisse GroupLower Price TargetUnderperformGBX 85 ➝ GBX 75
3/12/2019Peel HuntReiterated RatingHold
2/28/2019Numis SecuritiesReiterated RatingBuyGBX 163
2/28/2019Peel HuntLower Price TargetHoldGBX 175 ➝ GBX 155
2/12/2019Credit Suisse GroupDowngradeUnderperformGBX 170 ➝ GBX 85
2/1/2019Peel HuntReiterated RatingHold
1/16/2019JPMorgan Chase & Co.Reiterated RatingNeutral
1/15/2019Liberum CapitalReiterated RatingHoldGBX 176 ➝ GBX 115
1/15/2019Peel HuntReiterated RatingHold
1/7/2019Peel HuntReiterated RatingHold
1/2/2019JPMorgan Chase & Co.Reiterated RatingNeutral
12/6/2018Peel HuntReiterated RatingHold
11/1/2018Peel HuntReiterated RatingHold
10/31/2018Berenberg BankUpgradeHold
10/3/2018Peel HuntReiterated RatingHold
9/28/2018BarclaysDowngradeUnderweightGBX 190 ➝ GBX 130
9/25/2018Liberum CapitalReiterated RatingHoldGBX 176
9/24/2018Peel HuntReiterated RatingHoldGBX 278 ➝ GBX 175
9/18/2018Berenberg BankReiterated RatingSellGBX 120
9/18/2018Peel HuntReiterated RatingUnder Review
9/4/2018Peel HuntReiterated RatingUnder Review
8/24/2018Liberum CapitalReiterated RatingHold
8/10/2018Jefferies Financial GroupDowngradeHoldGBX 290 ➝ GBX 160
8/8/2018Credit Suisse GroupUpgradeNeutralGBX 250 ➝ GBX 215
8/8/2018Berenberg BankDowngradeSellGBX 290 ➝ GBX 120
8/8/2018Peel HuntReiterated RatingUnder Review
8/7/2018Numis SecuritiesLower Price TargetBuyGBX 296 ➝ GBX 280
8/7/2018JPMorgan Chase & Co.Lower Price TargetNeutralGBX 293 ➝ GBX 256
8/6/2018Liberum CapitalReiterated RatingHold
8/1/2018Peel HuntReiterated RatingAdd
7/17/2018Liberum CapitalReiterated RatingHold
7/17/2018Peel HuntReiterated RatingAdd
7/3/2018Peel HuntReiterated RatingAdd
6/22/2018Peel HuntInitiated CoverageAddGBX 278
4/30/2018Liberum CapitalReiterated RatingHoldGBX 265
3/22/2018Berenberg BankLower Price TargetBuyGBX 310 ➝ GBX 290
3/12/2018JPMorgan Chase & Co.Lower Price TargetNeutralGBX 339 ➝ GBX 293
3/5/2018BarclaysLower Price TargetEqual weightGBX 270 ➝ GBX 255
3/5/2018JPMorgan Chase & Co.Reiterated RatingNeutralGBX 339
3/2/2018Numis SecuritiesUpgradeBuyGBX 296
3/1/2018Liberum CapitalReiterated RatingHoldGBX 275
2/2/2018BarclaysInitiated CoverageEqual weightGBX 270
1/26/2018Liberum CapitalBoost Price TargetHoldGBX 270 ➝ GBX 275
1/17/2018Jefferies Financial GroupUpgradeBuyGBX 259 ➝ GBX 290
1/16/2018Numis SecuritiesReiterated RatingAddGBX 296
1/16/2018Liberum CapitalReiterated RatingHoldGBX 270
1/4/2018JPMorgan Chase & Co.Reiterated RatingNeutralGBX 339
11/29/2017Berenberg BankUpgradeBuyGBX 270 ➝ GBX 310
11/16/2017Liberum CapitalReiterated RatingHoldGBX 270
10/23/2017Numis SecuritiesReiterated RatingAddGBX 341
10/23/2017Liberum CapitalReiterated RatingHoldGBX 270
10/10/2017Liberum CapitalReiterated RatingHoldGBX 270
9/25/2017Jefferies Financial GroupLower Price TargetHoldGBX 350 ➝ GBX 259
9/21/2017Berenberg BankReiterated RatingHoldGBX 270
9/15/2017JPMorgan Chase & Co.Lower Price TargetNeutralGBX 376 ➝ GBX 339
9/14/2017Numis SecuritiesReiterated RatingAddGBX 350
9/14/2017Liberum CapitalReiterated RatingHoldGBX 350
8/31/2017Liberum CapitalLower Price TargetHoldGBX 365 ➝ GBX 350
7/26/2017Numis SecuritiesReiterated RatingAddGBX 375
7/21/2017Credit Suisse GroupReiterated RatingUnderperform
7/19/2017Liberum CapitalDowngradeHoldGBX 400 ➝ GBX 370
7/10/2017Liberum CapitalReiterated RatingBuyGBX 400
(Data available from 7/5/2017 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/7/2021
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/6/2022
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/5/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
3/7/2022
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/6/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/6/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/5/2022
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/5/2022

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Spire Healthcare Group logo
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments. The company also provides eye surgery and treatments, family planning, gastroenterology, general medicine, general surgery, haematology, hand surgery, hip and knee treatment, and heart and kidney treatments. In addition, it offers treatments in the areas of men's health, neurosurgery and neurology, paediatrics, pain management, rehabilitation, sports, physiotherapy, podiatry, respiratory care, and rheumatology; and scans and investigations, skin treatments, spinal care, sports science, urology care, vascular surgery, weight loss, and women's health. Further, the company offers various tests and scans, which include cardiac CT, CT, MRI, ultrasound, and X-ray scans. It offers diagnostics, in-patient, daycase, and out-patient care services through 40 hospitals and eight clinics across England, Wales, and Scotland. Spire Healthcare Group plc was founded in 2007 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 230.50
Low: 230.50
High: 239.26

50 Day Range

MA: GBX 219.25
Low: 205
High: 239.50

52 Week Range

Now: GBX 230.50
Low: 201
High: 256.50

Volume

351,010 shs

Average Volume

814,658 shs

Market Capitalization

£930.59 million

P/E Ratio

N/A

Dividend Yield

5.23%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Spire Healthcare Group?

The following equities research analysts have issued research reports on Spire Healthcare Group in the last twelve months: Barclays PLC, Berenberg Bank, JPMorgan Chase & Co., and Royal Bank of Canada.
View the latest analyst ratings for SPI.

What is the current price target for Spire Healthcare Group?

0 Wall Street analysts have set twelve-month price targets for Spire Healthcare Group in the last year. Their average twelve-month price target is GBX 271.75, suggesting a possible upside of 13.6%.
View the latest price targets for SPI.

What is the current consensus analyst rating for Spire Healthcare Group?

Spire Healthcare Group currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SPI will outperform the market and that investors should add to their positions of Spire Healthcare Group.
View the latest ratings for SPI.

How do I contact Spire Healthcare Group's investor relations team?

Spire Healthcare Group's physical mailing address is 3 Dorset Rise, LONDON, EC4Y 8EN, United Kingdom. The company's listed phone number is 44 20 7427 9000. The official website for Spire Healthcare Group is investors.spirehealthcare.com. Learn More about contacing Spire Healthcare Group investor relations.